ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

RegoNivo vs Standard of Care Chemotherapy in AGOC

ClinicalTrials.gov ID: NCT04879368

Public ClinicalTrials.gov record NCT04879368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Study identification

NCT ID
NCT04879368
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Enrollment
450 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Irinotecan Drug
  • Nivolumab Biological
  • Paclitaxel Drug
  • Regorafenib Drug
  • Trifluridine/Tipracil Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2021
Primary completion
Jul 8, 2025
Completion
May 31, 2026
Last update posted
Jul 16, 2025

2021 – 2026

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Mayo Clinic Arizona Scottsdale Arizona 85054
USC Norris Los Angeles California 90001
Siouxland Regional Cancer Center Sioux City Iowa 51101
St Elizabeth Healthcare Edgewood Kentucky 41017
Monument Health Rapid City Hospital Rapid City South Dakota 57701
Fred Hutchinson Cancer Research Centre - South Lake Union Clinic Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04879368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2025 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04879368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →